Narrowband ultraviolet B phototherapy for the treatment of pruritus induced by chronic liver disease and cholestasis

Narrowband ultraviolet B phototherapy for the treatment of pruritus induced by chronic liver disease and cholestasis - Narrowband ultraviolet B phototherapy for the treatment of pruritus induced by chronic liver disease and cholestasis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs052180032

Enrollment

Registered

2019-01-29

Start date

2019-01-01

Completion date

Unknown

Last updated

2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic liver disease or cholestasis including chronic hepatitis, cirrhosis, PSC, and PBC chronic liver disease

Interventions

Narrowband UVB phototherapy is performed once a week, starting at 0.3 to 0.5 J / cm2 and increasing by 0.05 to 0.1 J / cm2 (up to 1.5 J / cm2) depending on the therapeutic effect. The total number of

D010789

Narrowband ultraviolet B phototherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients eligible for preregistration were those: (i) with chronic liver disease or cholestasis including chronic hepatitis, cirrhosis, PSC, and PBC; (ii) who were at least 20 years of age at the time of informed consent; (iii) mean VAS>50 mm in one week, or VAS of >20 mm on 5 or more days per week, or pruritus scores >3 on 4 or more days per week.

Exclusion criteria

Exclusion criteria: Patients with psychiatric disorder, dementia, dermatosis, or chronic renal disease.

Design outcomes

Primary

Measure	Time frame
Utility of narrowband ultraviolet B phototherapy for patients with refractory hepatic pruritus	—

Contacts

Public ContactYuji Eso

Kyoto University Hospital

yujieso@kuhp.kyoto-u.ac.jp+81-75-751-4319

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026